Cabaletta Bio: Guggenheim Keeps Buy Rating, Raises PT to $16.

Tuesday, Mar 24, 2026 9:33 am ET1min read
CABA--

Cabaletta Bio: Guggenheim Keeps Buy Rating, Raises PT to $16.

Cabaletta Bio: Guggenheim Keeps Buy Rating, Raises PT to $16.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet